v3.21.2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
Preferred Stock
Series Seed Preferred Stock
Preferred Stock
Series A convertible preferred stock
Preferred Stock
Series A-2 convertible preferred stock
Preferred Stock
Series A-3 convertible preferred stock
Preferred Stock
Series CF convertible preferred stock
Preferred Stock
Series B convertible preferred stock
Common Stock
Additional Paid-in Capital
Subscription Receivable
Accumulated Deficit
Series A-3 convertible preferred stock
Series CF convertible preferred stock
Total
Beginning balance (in shares) at Dec. 31, 2019 20,714,518 5,654,072 5,932,742 8,223,036 126,641   664,167            
Beginning balance at Dec. 31, 2019 $ 2,071 $ 565 $ 593 $ 823 $ 12   $ 66 $ 15,486,050 $ (22,677) $ (22,617,702)     $ (7,150,199)
Issuance of Series A-3 preferred stock (in shares)       809,294                  
Issuance of Series A-3 preferred stock       $ 81       428,845 (117,614)       311,312
Issuance of Series B preferred stock (in shares)           20,754,717              
Issuance of Series B preferred stock           $ 2,075   10,997,925         11,000,000
Offering costs               (31,690)         (31,690)
Fair value of warrant issuances - venture debt               58,421         58,421
Stock-based compensation               49,932         49,932
Net loss                   (1,906,527)     (1,906,527)
Ending balance at Mar. 31, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 12 $ 2,075 $ 66 26,989,483 (140,291) (24,524,229)     2,331,249
Ending balance (in shares) at Mar. 31, 2020 20,714,518 5,654,072 5,932,742 9,032,330 126,641 20,754,717 664,167            
Beginning balance (in shares) at Dec. 31, 2019 20,714,518 5,654,072 5,932,742 8,223,036 126,641   664,167            
Beginning balance at Dec. 31, 2019 $ 2,071 $ 565 $ 593 $ 823 $ 12   $ 66 15,486,050 (22,677) (22,617,702)     (7,150,199)
Issuance of Series A-3 preferred stock (in shares)                     809,294 709,690  
Net loss                         (8,088,980)
Ending balance at Sep. 30, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 66 27,384,036 (13,454) (30,706,682)     (3,329,743)
Ending balance (in shares) at Sep. 30, 2020 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 664,167            
Beginning balance (in shares) at Mar. 31, 2020 20,714,518 5,654,072 5,932,742 9,032,330 126,641 20,754,717 664,167            
Beginning balance at Mar. 31, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 12 $ 2,075 $ 66 26,989,483 (140,291) (24,524,229)     2,331,249
Issuance of Series CF preferred stock (in shares)         709,690                
Issuance of Series CF preferred stock         $ 71     286,447         286,518
Issuance of Series A-3 preferred stock                 126,837       126,837
Stock-based compensation               49,932         49,932
Net loss                   (2,267,597)     (2,267,597)
Ending balance at Jun. 30, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 66 27,325,862 (13,454) (26,791,826)     526,939
Ending balance (in shares) at Jun. 30, 2020 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 664,167            
Offering costs               (28,756)         (28,756)
Fair value of warrant issuances - venture debt               81,151         81,151
Stock-based compensation               5,779         5,779
Net loss                   (3,914,856)     (3,914,856)
Ending balance at Sep. 30, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 66 27,384,036 $ (13,454) (30,706,682)     (3,329,743)
Ending balance (in shares) at Sep. 30, 2020 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 664,167            
Beginning balance (in shares) at Dec. 31, 2020 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 664,167            
Beginning balance at Dec. 31, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 66 27,481,995   (33,345,997)     (5,857,645)
Stock-based compensation               36,976         36,976
Net loss                   (3,023,935)     (3,023,935)
Ending balance at Mar. 31, 2021 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 66 27,518,971   (36,369,932)     (8,844,604)
Ending balance (in shares) at Mar. 31, 2021 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 664,167            
Beginning balance (in shares) at Dec. 31, 2020 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 664,167            
Beginning balance at Dec. 31, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 66 27,481,995   (33,345,997)     (5,857,645)
Conversion of preferred stock into common stock                         6,291
Conversion of debt into common stock                         2,680,289
Conversion of related party notes and payables into common stock                         257,515
Issuance of common stock pursuant to equity line of credit                         367,696
Net loss                         (22,659,480)
Ending balance at Sep. 30, 2021             $ 1,263 57,467,015   (56,005,477)     1,462,801
Ending balance (in shares) at Sep. 30, 2021             12,627,488            
Beginning balance (in shares) at Mar. 31, 2021 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 664,167            
Beginning balance at Mar. 31, 2021 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 66 27,518,971   (36,369,932)     (8,844,604)
Conversion of preferred stock into common stock $ (2,071) $ (565) $ (593) $ (904) $ (83) $ (2,075) $ 403 5,888          
Conversion of preferred stock into common stock (shares) (20,714,518) (5,654,072) (5,932,742) (9,032,330) (836,331) (20,754,717) 4,027,181            
Issuance of common stock in public offering             $ 241 9,999,761         10,000,002
Issuance of common stock in public offering (in shares)             2,409,639            
Offering costs               (2,116,957)         (2,116,957)
Exercise of over-allotment option             $ 36 1,364,961         1,364,997
Exercise of over-allotment option (in shares)             361,445            
Conversion of debt into common stock             $ 114 2,680,175         2,680,289
Conversion of debt into common stock (in shares)             1,135,153            
Conversion of related party notes and payables into common stock             $ 15 257,500         257,515
Conversion of related party notes and payables into common stock (in shares)             152,357            
Common stock and warrants issued in connection with note             $ 2 73,956         73,958
Common stock and warrants issued in connection with note (in shares)             20,000            
Common stock issued in connection with business combination             $ 219 8,025,323         8,025,542
Common stock issued in connection with business combination (in shares)             2,192,771            
Exercise of warrants             $ 3 145,693         145,696
Exercise of warrants (in shares)             31,881            
Common stock issued pursuant to consulting agreement             $ 5 182,995         183,000
Common stock issued pursuant to consulting agreement (in shares)             50,000            
Stock-based compensation               3,801,553         3,801,553
Net loss                   (10,697,498)     (10,697,498)
Ending balance at Jun. 30, 2021             $ 1,104 51,939,819   (47,067,430)     4,873,493
Ending balance (in shares) at Jun. 30, 2021             11,044,594            
Common stock issued in connection with business combination             $ 110 3,403,086         3,403,196
Common stock issued in connection with business combination (in shares)             1,101,538            
Exercise of warrants             $ 36 1,622,314         1,622,350
Exercise of warrants (in shares)             355,000            
Stock-based compensation               134,113         134,113
Issuance of common stock pursuant to equity line of credit             $ 13 367,683         367,696
Issuance of common stock pursuant to equity line of credit (in shares)             126,356            
Net loss                   (8,938,047)     (8,938,047)
Ending balance at Sep. 30, 2021             $ 1,263 $ 57,467,015   $ (56,005,477)     $ 1,462,801
Ending balance (in shares) at Sep. 30, 2021             12,627,488